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When germ-free cell cultures became a laboratory routine, hopes were high for using this novel technology for treatment of diseases
or replacement of cells in patients suffering from injury, inflammation, or cancer or even refreshing cells in the elderly. Today, more
than 50 years after the first successful bone marrow transplantation, clinical application of hematopoietic stem cells is a routine
procedure, saving the lives of many every day. However, transplanting other than hematopoietic stem and progenitor cells is still
limited to a few applications, and it mainly applies to mesenchymal stromal cells (MSCs) isolated from bone marrow. But research
progressed and different trials explore the clinical potential of humanMSCs isolated from bone marrow but also from other tissues
including adipose tissue. Recently,MSCs isolated frombonemarrow (bmMSCs)were shown to be a blend of distinct cells andMSCs
isolated from different tissues show besides some common features also some significant differences. This includes the expression
of distinct antigens on subsets of MSCs, which was utilized recently to define and separate functionally different subsets from bulk
MSCs. We therefore briefly discuss differences found in subsets of human bmMSCs and inMSCs isolated from some other sources
and touch upon how this could be utilized for cell-based therapies.
1. Introduction
The MSCs have been described for the first time as colony
forming fibroblasts (CFU-F), a rare population of cells resid-
ing in the bone marrow of guinea-pigs or mice [1, 2]. Other
researchers isolated MSCs from bone marrow of rabbits [3],
rats [4], pigs [5], and other species. Human bmMSCs were
described in the late nineties as well [6] and at the same time
a breakthrough study investigated the expression of typical
cell surface markers and the proliferation and differentiation
properties of human MSCs in more detail [7]. In the last
20 years, a huge number of studies investigated phenotypic
features and facts of MSCs. In July 2015, a web search yielded
more than 357 000 hits for the term “mesenchymal stem cell”
(Google Scholar; Table 1). At the same time PubMed listed
about 35 000 citations, and Web of Science listed about 134
000 publications for this term.
When the biological properties of MSCs were explored
in more detail, questions arose whether these cells met the
criterion of a true stem cell [8]. To qualify as a stem cell, these
cells must be able to self-renew, most likely by symmetric cell
division to produce two daughter cells with the same stem
cell qualities. At the same time, by asymmetric cell division
or after specific activation, stem cells must be able to generate
more mature progenitor cells or differentiated effector cells
(Figure 1). Nowadays, experts agree that MSCs may generate
upon appropriate stimulation quite different mature cells
including osteoblasts, chondrocytes, tenocytes, adipocytes,
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Table 1: Overview of studies published regarding MSCs using the
term “stem cell” or “stromal cell” in the last 20 years accessed by
a web search in July 2015 (Google Scholar). It seems that the term
“stem cell” became more popular although the “stemness” was only
shown in a more strict sense for MSCs involved in osteogenesis and
bone repair.
Search Hits Hits
Year MSC as “stem” cell MSC as “stromal” cell
1995–2000 12,000 12,100
2000–2005 41,000 21,700
2005–2010 156,000 38,200
2010–2015 148,000 33,600
smooth muscle cells, and stromal cells of the bone marrow
[9].They display differentiation capacities and therefore qual-
ify as multipotent progenitor cells (Figure 1). To qualify as
stem cells, self-renewal has to be shown as well [10].
Expansion of MSCs was shown to be limited to a few
passages of in vitro culture and the cells underwent replicative
senescence [11]. Changes in the differentiation potential of
MSCs after in vitro expansion were noted and chondrogenic
clones especially disappeared early on [12]. Therefore, avail-
able in vitro protocols for expansion of MSCs do not yield
true stem cells.MSCswere also investigated for stem cell qual-
ities in vivo. By consecutive transplantation, MSCs were able
to maintain their osteogenic progenitor potential and spon-
taneous heterotopic ossification was observed [13]. Sponta-
neous generation of cartilaginous or adipose tissue was not
observed experimentally after heterotopic implantation of
MSCs suggesting that at least bmMSCs are self-renewing
stem cells for skeletal tissue regeneration, but not stem cells
for regeneration of cartilage, fat, and other tissues [13].There-
fore, in a strict sense the term mesenchymal stem cell applies
only for osteogenesis or bone regeneration and consequently,
for general purposes, the term mesenchymal stromal cell is
preferred nowadays.
2. Sources for Mesenchymal Stromal Cells
Mesenchymal stromal cells have been described in and have
been isolated from many different adult tissues, including
bone marrow, adipose tissue, inner organs, and blood vessels
and from rather “young sources” such as amniotic fluid,
amniotic membrane, umbilical cord, or placenta [2, 14–22].
In order to be able to discriminateMSCs from fibroblasts and
other adherently growing cells, a group of experts suggested
defining bmMSCs by expression of a set of cell surface mark-
ers, a trilineage differentiation potential (osteogenic, chon-
drogenic, and adipogenic), and fibroblast-like appearance in
in vitro culture [23] (Figure 2). There is ample experimental
evidence that MSCs isolated from tissues other than bone
marrow share these features and generate upon stimulation
osteoblasts, chondrocytes, adipocytes, and other cells in vitro
as well [24–29]. However, until now, there is no experimental
evidence that MSC preparations from any source contain
progenitor cells that spontaneously generate fat or cartilage
after transplantation to ectopic sites.
Osteoblast
MSC
Self-renewal Differentiation
MSC
Chondrocyte
Adipocyte
Figure 1: Overview on self-renewal or differentiation of stem cells
in their respective stem cell niche.
In avascular tissues such as cartilage, MSC-like cells
meeting the inclusion criteria defined by the consensus con-
ference were detected as well [31–33]. Their relation to MSCs
derived from vascularized tissues, blood vessels, or serum is
a matter of debate for quite some years now [34]. Still, to our
momentary knowledge MSCs and MSC-like cells from dif-
ferent sources share characteristics including those features
used to define the adultMSCs [23].However, exploringMSCs
from different sources in more detail revealed significant
differences (see below).
In an adult organism and in sharp contrast to hematopoi-
etic stem and progenitor cells [35] or spermatogonial stem
cells [36], MSCs do not have stringent requirements for a
stem cell niche [8], but they attach well to fibronectin, colla-
gens, laminins, and other extracellular matrix proteins [37,
38]. MSCs were shown to appear upon adaptive transfer at
several sites in a healthy recipient, and only a few cells home
to bone marrow [39, 40]. Up to now, differences between
the homing of MSCs to bone marrow and MSCs detected
in other locations or trapped in the veins of the lung after
intravenous injection ofMSCs are not completely understood
[40]. Moreover, the overall efficacy of homing or grafting of
MSCs is low, but someMSCs applied by intravenous injection
are found even at sites of injury [40]. At the same time,
mobilization of MSCs occurs upon hypoxia or after injury,
indicating a correlation between the migratory capacities of
MSC and local wound repair [41]. A strong affinity of MSCs
to a defined and specialized niche would possibly hinder the
main function of these multipotent repair cells and prevent
their migration to damaged sites [42, 43].
3. Differences in the Transcriptome of
MSCs from Different Sources
Prima vista MSCs from different tissues share key charac-
teristics such as fibroblast-like appearance in vitro, trilineage
differentiation capacity, expression of certain cell surface anti-
gens (e.g., CD73, CD90, and CD105), and lack of expression
of others (e.g., CD11b, CD14, CD19, CD34, CD45, CD78, and
MHC class II; Figure 2) [23, 29, 44]. Most of the studies
investigating the expression of marker genes of MSCs have
been performed with cells after in vitro expansion and cell
culture conditions showed significant influence on the tran-
scriptome of MSCs. For instance, bmMSCs can be isolated
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Figure 2: Human mesenchymal stromal cells from bone marrow (bmMSCs) are defined by their expression of CD73, CD90, and CD105,
by lack of expression of a series of other cell surface markers such as CD11b, CD34, and CD45, and by a fibroblastoid appearance (a) and
trilineage differentiation to generate chondrocytes (b), osteoblasts (c), or adipocytes (d) (for further details see [23]).
and explored ex vivo without time-consuming procedures
and without proteolytic digestion [45]. Human bmMSCs
express ex vivo the receptor for nerve growth factor (CD271),
but its expression is lost by expansion of the cells in vitro
[30, 46]. Comparably, expression of CD34 on MSCs from
adipose tissue (atMSCs) is detected on cells ex vivo. However,
it is variable and depends on the cell culture conditions
[28]. Therefore, a comparison of the transcriptome of freshly
isolated MSCs from different sources seems biased at least to
some extent by methods employed for isolation and prepa-
ration of the cells. Furthermore, the transcriptome of MSCs
from different sources is probably influenced after expansion
at least to some degree by the cell culture conditions as well.
In early passages of in vitro expansion, MSCs from differ-
ent sources maintain some distinct features.This statement is
supported by several studies.The proliferating ability and the
gene expression of human bmMSCs and atMSCs were com-
pared [47]. The elevated proliferative capacity of atMSCs was
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Figure 3: Comparing the total transcriptome of humanMSCs from
bone marrow (bmMSCs), from the amniotic site of human term
placenta (paMSC), and from the maternal, endometrial part of
human term placenta (pmMSC) in the second passage of in vitro
expansion. MSCs from placenta are similar, but bmMSCs are clearly
different from placenta derived MSCs.
associated with an elevated expression of transcription factor
Dickkopf (DKK) 1. The DKK family of genes encodes soluble
factors that participate in the development of mesenchymal
tissues and interact with theWnt-regulated pathway. Overall,
the transcriptome of human bmMSCs and atMSCs appeared
highly similar but several factors accounting for about 1%
of all genes investigated are expressed at significantly differ-
ent levels [47]. This highly similar gene expression profile
was taken as evidence that MSCs in all tissues might be
derived from a common mesenchymal precursor. Another
study investigated the gene expression in neonatal MSCs
isolated from umbilical cord blood (ucb-MSCs) from dif-
ferent donors with published gene-array data [48]. Again,
bmMSCs appeared highly similar to ucb-MSCs, and the
expression of five transcripts (genes) had not been reported in
MSCs before (MGC3047, MGC17528, MGC3278, FLJ12442,
and AGENCOURT 6683145) [48]. This study was extended
by exploring the transcriptome of ucb-MSCs compared to
MSCs isolated from the corresponding umbilical cord, where
MSCs are found enriched in Wharton’s jelly [49]. In this
case, from a total of 13,699 genes investigated 1,870 were
transcribed at significantly different levels representing 6% of
all annotations computed [49].
When comparing theMSCs fromamniotic sites of human
term placenta with MSCs from the maternal, endometrial
site of the placenta, differences were noted in the transcrip-
tome and more than 100 genes were expressed significantly
different (Figure 3). In these gene-array experiments human
bmMSCs served as controls, and the differences in their tran-
scriptome compared to both the placenta-derivedMSCs from
the amniotic site (paMSCs, i.e., fetal MSCs) and placenta-
derived MSCs from the endometrial site (pmMSCs, i.e.,
maternal MSCs) are obvious even to a layperson (Figure 3).
We recently confirmed that paMSCs and pmMSCs can be
separated with simple methods at a sufficient efficacy as the
lengths of the telomeres in paMSCs were significantly longer
compared to the corresponding pmMSCs after measuring
only a few samples [50]. This finding supports earlier studies
reporting on higher and extendedmitotic activity of neonatal
MSCs, a distinct differentiation potential, and extended life
span in vitro [51].
A comparison of the transcriptome of MSCs over time
during in vitro expansion revealed that at least within early
passages the transcriptome was stable and did not change
significantly between cells in their third compared to the sixth
passage of culture. At the same time, the expression of a set of
core genes was preserved in bmMSCs and all neonatal MSCs
were investigated, as were the differences found between
bmMSCs and different MSCs from neonatal tissues [52].
Others report on significant differences in the tran-
scriptome of bmMSCs compared to islet-derived precursor
cells (IdPCs) [19] which met the minimal criteria set for
bmMSCs [23]. Differences in their transcriptomes yielded
distinct patterns for factors associated with gland, muscular,
ectodermal, and nervous system development [19]. The dif-
ferences between the transcriptomes can be associated with
the differences in the origin of the cells during embryonic
development: bmMSCs are derived from limb anlagen and
IdPCs are derived from trunk anlagen. However, in this
study bmMSCs and IdPCs were expanded in slightly different
media [19].Therefore, a bias regarding cell culture conditions
cannot be excluded.
However, small differences in the transcriptome reported
between MSCs from different sources do have a noticeable
impact on the behaviour of the cells. Recently, we found a
significant difference between bmMSCs andplacenta-derived
MSCs (pMSCs) not only in the expression of the cell surface
molecule CD146 and the membrane-anchored alkaline phos-
phatase [53], but also in the expression of transcription factor
Runx2 [50], a gene associated with bone development. In
Runx2-targeted mice (Runx2−/−) endochondral ossification
is completely absent as differentiation of MSCs to osteoblasts
requires this transcription factor [54]. Therefore, differences
in ossification observed in bmMSCs compared to pMSCs not
only depend on a distinct expression of alkaline phosphatase
in bmMSCs but also correlate with significant differences
of regulatory factors in these cell types. At present, it can
be only speculated whether the differences in expression of
transcription factors influence the homing of bmMSCs versus
pMSCs, atMSCs, or other MSCs [19, 50]. Of note, differences
in expression of integrin components, for instance, between
bmMSCs and atMSCs, have been reported, and for atMSC
specific marker genes were defined [27]. Furthermore, there
is compelling evidence that MSCs isolated from different
sources but expanded under identical conditions share key
features as defined by the so-called minimal criteria [23],
but small differences in the expression of a few genes yield a
significantly different type of cells when it comes to regulation
of proliferation or differentiation of bmMSCs compared to
MSCs from other sources [50, 52, 55].Therefore, preselection
of the best source of MSCs and possibly even preselection
of subsets of MSCs may become an issue in the context of
clinical applications.
Studies exploring the total transcriptome of the cells
followed by bioinformatics and systems biology confirm that
MSCs from different sources are very closely related cells. In
this sense, the minimal criteria defined almost a decade ago
seem to not only describe these cells in a correct way but also
discriminate the MSCs from other progenitor cells including
the hematopoietic progenitor cells or endothelial progenitor
cells, found sometimes in the same niche efficiently [23].
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Figure 4: Schematic draft of the experimental strategy to define and functionally characterize subsets of human bmMSCs. MSCs were sorted
by fluorescence-activated cell sorting (FACS) (left panel). From the mononuclear cells the CD271+ subset, which is gated in R1, was further
subdivided by staining with two additional antibodies to TNAP and CD56 positive cells (gates R2 and R3, middle panel). The populations
defined by R2 or R3 were expanded in separate cultures and their proliferation and differentiation were compared (right panel) (for further
details see [30]).
4. Differences in MSC Subsets from
Bone Marrow
In routine procedures most laboratories isolate bulk MSC
populations and enrich mesenchymal stromal cells by a
combination of plastic adherence followed by expansion of
the cells in media preferring proliferation of MSCs [7]. Alter-
natively, MSCs can be isolated from bone marrow, peripheral
blood, or amniotic fluid by simple gradient centrifugation
and subsequently a given subset can be isolated using mon-
oclonal antibodies to detect specific cell surface antigens
expressed on some [30] but not on all MSCs [30, 45, 56].
For separation of such subsetsmagnetic-activated cell sorting
(MACS) or fluorescence-activated cell sorting (FACS) is used.
Accordingly, some of the proliferation- and differentiation-
competent human bmMSCs showed expression of the recep-
tor for nerve growth factor (CD271) and the tissue nonspecific
alkaline phosphatase (TNAP), previously referred to as mes-
enchymal stem cell antigen- (MSCA-) 1 [30, 45].The CD271+
subset was further subdivided using monoclonal antibodies
including anti-CD56 clone 39D5. Upon expansion of the
CD271+ TNAP+ CD56+ and the CD271+ TNAP+ CD56−
MSC subsets in individual cultures, an interesting functional
difference was observed: the CD56+ cells were proliferative
andmore chondrogenic, but less adipogenic compared to the
corresponding CD56− cells (Figure 4). This study provided
evidence that even a preselected subset of bmMSCs such as
the CD271+ mesenchymal cells can be further subdivided in
smaller fractions. It also supports the hypothesis that bmM-
SCs are ex vivo blend of cells. Accordingly, CD90+, VCAM-
1+, and CD271+ bmMSCs represent another distinct bmMSC
subset of cells [57, 58]. Other monoclonal antibodies defined
otherMSC subsets [45] and some of these antigenswere char-
acterized on MSCs in more detail recently [59]. Moreover, a
population of bmMSCs with low expression of the PDGF
receptor alpha (PDGFR𝛼) was considered as the primary
mesenchymal stromal cell [60]. Interestingly, PDGFR𝛼+,
CD51+, and nestin+ MSCs were shown to play a key role
for generating a stem cell niche for hematopoiesis [61, 62], a
feature of human bmMSCs previously associatedwith expres-
sion of CD146 [63].
However, nowadays not all MSC subsets as defined by
monoclonal antibodies ex vivo or in vitro can be associated
with functional differences, and the differences between such
subsets were defined by in vitro tests. Moreover, homing
experiments with bulk bmMSCs followed by detection of
MSCs at sites different from bone marrow in the recipient
are not definitive proof that bmMSC subsets represent cells
with distinct physiological tasks as homing of MSCs can be a
passive trapping in irrelevant tissues.
Due to technical limitations it is not well studied if com-
parable subsets of cells can be defined ex vivo in MSCs from
more niches such as adipose tissue, placenta, and perivas-
cular sites in inner organs or others. It might be that the
mesenchymal stem cell is only present in adult bone marrow
and other niches contain progenitor MSCs with a distinct
tissue specificity. Alternatively, the niche forMSCsmay be the
bone marrow harbouring or attracting stem cell-like MSCs
and distinct subsets of MSCs. Thus, after i.v. injection the
stem cell-like MSCs and distinct MSC subsets will primarily
migrate to bonemarrow of the recipient. However, albeit with
low efficacy, they also appear at other sites of a recipient.
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Inflammation and processes of tissue repair will then mod-
ulate the homing of MSCs and attract those MSC subsets
needed for local regeneration.
5. MSC Subsets and Translation in
Clinical Applications
The multipotent MSCs are an attractive cellular tool for
regenerative medicine and tissue engineering [9] and more
than 350 clinical trials involving MSCs are reported in the
web-based registry ClinicalTrials.gov. Most studies reported
focus on musculoskeletal tissues, circulation and ischemia,
gastrointestinal conditions, and the nervous system [64].
Application of MSCs in clinical trials has been considered
rather safe but some concerns remain [65, 66]. A recent
study pointed out that in less than half of all clinical cellular
trials reported to the FDA a tumorigenicity test of the
cells employed was performed [67]. Other questions arise
from the investigations performed during preclinical studies
[68]. However, nowadays there is considerable experience
with application of MSCs to treat graft-versus-host disease
(GvHD). If MSCs would have a considerable risk to generate
tumours or other adverse types of cells, one would expect
that such significant problems come to the surface especially
in patients after bone marrow transplantation and immune
suppression [69].
One important concern for the safety of patients is
of course the expansion of MSCs in vitro. Here an enor-
mous variability of protocols exists and in particular studies
utilizing cells from industrial sources rarely disclose the
exact methods employed in cell production. For preclinical
trials and more so for clinical safety and feasibility studies
standardized methods or open publication of all procedures
involved in cell production would be advantageous [64].
Applying bulk MSCs in a clinical context has technical
advantages. The preparation of cells does not involve addi-
tional steps for selection or adaptation of theMSCs andmany
cells can be produced. As outlined above, MSCs prepared
by standard procedures (attachment to plastic, preferred
outgrowth by choice of medium) contain distinct subsets
of cells. Applying, for instance, bmMSCs to treat muscular
defects may yield local ossification, sometimes called hetero-
topic ossification [13, 70]. In this context, a selection of less
osteogenic MSCs may help to avoid adverse effects. This can
be done by changing the source of MSCs, for instance, by
takingMSCs from adipose tissue or termplacenta rather than
bonemarrow to regenerate muscle tissue or vasculature or by
depleting the MSCs from the osteogenic subset. A significant
correlation between expression of alkaline phosphatase—
an enzyme needed for mineralization of bony tissue—
Runx2—the key regulator of osteogenic differentiation of
mesenchymal precursor cells—and CD146 was reported [22,
50] and using an antibody to CD146 allowed to separatemore
osteogenic from less osteogenic cells. A method to select
more adipogenic or chondrogenic MSCs has been reported
recently as well [30] (Figure 4). When used in a clinical con-
text, determination or selection ofMSC subsets by antibodies
and flow cytometry will require standards for the technology
applied [28, 37, 71], as in some cases small subsets of cells
have to be defined [45]. Cell culture conditions influence the
expression of cell surface antigens [28, 37], and even mono-
clonal antibodies yield variable results including false positive
staining depending on the exact experimental conditions
[72].
6. Conclusions
BulkMSCs have been applied to ameliorate graft-versus-host
disease or to treat autoimmune diseases for more than a
decade now. Therefore, their clinical use is considered to be
very safe. However, in this context it is important to recall that
the route of application (i.v.) used for immunosuppression
by MSCs may help to select the type of MSCs needed in
the hematopoietic niche in bone marrow or in the blood
system, because MSCs not matching the respective niches
will be either trapped somewhere else or will be discarded. In
contrast, the mechanisms contributing to the correct homing
of MSCs to bone marrow or sites of tissue regeneration or
other natural selective processes may not work well or not
work at all in cases of a local administration of the cells, for
instance, in the heart, in muscles, or in inner organs. There-
fore, as there is no natural selection process forMSCs applied
locally, a technical preselection could enrich the MSC subset
needed clinically, as local application of a blend of MSCs may
contain many unwanted cells. Some of the strategies to select
or deplete subsets ofMSCs have been discussed in this review.
Nevertheless, today our knowledge on functional differences
of MSC subsets is still not complete.
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